EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing rescues perfusion and diabetic ischemic wound healing

Sumit S Verma, Chandan K Sen, Rajneesh Srivastava, Surya C Gnyawali, Parul Katiyar, Ajay K Sahi, Manishekhar Kumar, Yashika Rustagi, Sheng Liu, Diksha Pandey, Ahmed S Abouhashem, Leila N W Fehme und 8 weitere

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.01.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Sumit S Verma und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA; Department of Surgery, India…. Hauptthemen laut MEDLINE: Wound Healing, Phospholipase C gamma, Ischemia, Epigenesis, Genetic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, U.S. Department of Defense, Commonwealth of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic wounds are complicated by underlying peripheral vasculopathy. Reliance on vascular endothelial growth factor (VEGF) therapy to improve perfusion makes logical sense, yet clinical study outcomes on rescuing diabetic wound vascularization have yielded disappointing results. Our previous work has identified that low endothelial phospholipase Cγ2 (PLCγ2) expression hinders the therapeutic effect of VEGF on the diabetic ischemic limb. In this work, guided by single-cell RNA sequencing of human wound edge, we test the efficacy of gene-targeted therapeutic demethylation intending to improve VEGF-mediated neovascularization. PLCγ2 expression was diminished in all five identified diabetic wound-edge endothelial subclusters encompassing arterial, venous, and capillary cells. Such low expression was associated with hypermethylated PLCγ2 promoter. PLCγ2 promoter was also hypermethylated at murine diabetic ischemic wound edge. To specifically demethylate endothelial PLCγ2 promoter during VEGF therapy, a CRISPR-dCas9-based demethylation cocktail was delivered to the ischemic wound edge using tissue nanotransfection (TNT) technology. Demethylation-based upregulation of PLCγ2 during VEGF therapy improved wound tissue blood flow with an increased abundance of von Willebrand factor (vWF)+/PLCγ2+ vascular tissue elements by activating p44/p42-mitogen-activated protein kinase (MAPK) → hypoxia-inducible factor [HIF]-1α pathway. Taken together, TNT-based delivery of plasmids to demethylate the PLCγ2 gene promoter activity led to significant improvements in VEGF therapy for cutaneous diabetic wounds, resulting in better perfusion and accelerated wound closure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wound HealingPhospholipase C gammaIschemiaEpigenesis, GeneticGene EditingAnimalsHumansMicePromoter Regions, GeneticVascular Endothelial Growth Factor ADNA MethylationNeovascularization, PhysiologicDiabetes Mellitus, ExperimentalEndothelial CellsDisease Models, AnimalMaleCRISPR-Cas SystemsTransfection

Stichwörter der Autor:innen

CRISPRDNA methylationPLCγ2VEGF therapyangiogenesisdiabetesepigeneticssingle-cell RNA sequencingwound

Substanzen

Phospholipase C gammaVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA; Department of Surgery, Indiana Center for Regenerative Medicine and Engineering, Indiana Universit…
  • Department of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA.
  • Department of Surgery, Indiana Center for Regenerative Medicine and Engineering, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  • Center for Computational Biology and Bioinformatics (CCBB), Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Förderung

  • NIDDK NIH HHS
  • U.S. Department of Defense
  • Commonwealth of Pennsylvania
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • US Office of Congressionally Directed Medical Research Programs

Zitieren

APA

Verma, S. S., Sen, C. K., Srivastava, R., Gnyawali, S. C., Katiyar, P., Sahi, A. K., Kumar, M., Rustagi, Y., Liu, S., Pandey, D., Abouhashem, A. S., Fehme, L. N. W., Kacar, S., Mohanty, S. K., Faden-McCormack, J., Murphy, M. P., Roy, S., Wan, J., Yoder, M. C., & Singh, K. (2025). Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing rescues perfusion and diabetic ischemic wound healing. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.01.034

Vancouver

Verma SS, Sen CK, Srivastava R, Gnyawali SC, Katiyar P, Sahi AK, et al. Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing rescues perfusion and diabetic ischemic wound healing. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.01.034

BibTeX
@article{Verma2025,
  author = {Verma, Sumit S and Sen, Chandan K and Srivastava, Rajneesh and Gnyawali, Surya C and Katiyar, Parul and Sahi, Ajay K and Kumar, Manishekhar and Rustagi, Yashika and Liu, Sheng and Pandey, Diksha and Abouhashem, Ahmed S and Fehme, Leila N W and Kacar, Sedat and Mohanty, Sujit K and Faden-McCormack, Julie and Murphy, Michael P and Roy, Sashwati and Wan, Jun and Yoder, Mervin C and Singh, Kanhaiya},
  title = {Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing rescues perfusion and diabetic ischemic wound healing},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.01.034}
}
Kostenlos starten →